ES2696074T3 - Tratamiento del cáncer de mama - Google Patents

Tratamiento del cáncer de mama Download PDF

Info

Publication number
ES2696074T3
ES2696074T3 ES12846720T ES12846720T ES2696074T3 ES 2696074 T3 ES2696074 T3 ES 2696074T3 ES 12846720 T ES12846720 T ES 12846720T ES 12846720 T ES12846720 T ES 12846720T ES 2696074 T3 ES2696074 T3 ES 2696074T3
Authority
ES
Spain
Prior art keywords
trip trip
tio
tra
breast cancer
amen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12846720T
Other languages
English (en)
Spanish (es)
Inventor
Andrew A Protter
Jennifer Richer
Dawn Cochrane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Prostate Therapeutics LLC
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
Medivation Prostate Therapeutics LLC
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2696074(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics LLC, University of Colorado System, University of Colorado Colorado Springs filed Critical Medivation Prostate Therapeutics LLC
Application granted granted Critical
Publication of ES2696074T3 publication Critical patent/ES2696074T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12846720T 2011-07-29 2012-07-27 Tratamiento del cáncer de mama Active ES2696074T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
ES2696074T3 true ES2696074T3 (es) 2019-01-14

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12846720T Active ES2696074T3 (es) 2011-07-29 2012-07-27 Tratamiento del cáncer de mama

Country Status (18)

Country Link
US (4) US9517229B2 (enExample)
EP (4) EP2739153B1 (enExample)
JP (2) JP6158180B2 (enExample)
KR (1) KR101923250B1 (enExample)
CN (1) CN103997894B (enExample)
BR (1) BR112014002200A2 (enExample)
CA (1) CA2843417C (enExample)
CY (1) CY1121038T1 (enExample)
DK (1) DK2739153T3 (enExample)
EA (1) EA028452B1 (enExample)
ES (1) ES2696074T3 (enExample)
HU (1) HUE040524T2 (enExample)
MX (1) MX359664B (enExample)
PH (1) PH12014500248B1 (enExample)
PL (1) PL2739153T3 (enExample)
PT (1) PT2739153T (enExample)
SI (1) SI2739153T1 (enExample)
WO (1) WO2013066440A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
DK2945628T3 (da) * 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP3065549A4 (en) * 2013-11-07 2017-05-24 Deciphera Pharmaceuticals, LLC Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP3148336B1 (en) * 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
RU2017120330A (ru) * 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019387367A1 (en) * 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
JP2023536636A (ja) * 2020-08-03 2023-08-28 オンコサイト・コーポレイション 腫瘍の分類及び応答性の予測
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2608436C (en) 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
ES2689292T3 (es) * 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
EP2220050A2 (en) * 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
US8524755B2 (en) * 2009-02-24 2013-09-03 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
US10175240B2 (en) 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
RU2017120330A (ru) 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы

Also Published As

Publication number Publication date
CY1121038T1 (el) 2019-12-11
US20190262315A1 (en) 2019-08-29
EP3610731A1 (en) 2020-02-19
PH12014500248A1 (en) 2014-03-17
WO2013066440A9 (en) 2013-07-18
JP2014524934A (ja) 2014-09-25
PH12014500248B1 (en) 2018-08-31
DK2739153T3 (en) 2018-12-03
CN103997894A (zh) 2014-08-20
EP2739153A4 (en) 2015-03-11
CA2843417C (en) 2018-08-21
US20140296312A1 (en) 2014-10-02
US10111861B2 (en) 2018-10-30
US9517229B2 (en) 2016-12-13
HK1198867A1 (en) 2015-06-19
JP2017141269A (ja) 2017-08-17
HUE040524T2 (hu) 2019-03-28
US20210069154A1 (en) 2021-03-11
PT2739153T (pt) 2018-11-28
MX2014001218A (es) 2014-08-22
HK1201413A1 (en) 2015-09-04
SI2739153T1 (sl) 2018-12-31
BR112014002200A2 (pt) 2017-03-07
EP3430907A1 (en) 2019-01-23
KR101923250B1 (ko) 2018-11-28
EA028452B1 (ru) 2017-11-30
EP3791724A1 (en) 2021-03-17
PL2739153T3 (pl) 2019-04-30
JP6158180B2 (ja) 2017-07-05
KR20140107174A (ko) 2014-09-04
EA201400178A1 (ru) 2014-11-28
CN103997894B (zh) 2016-08-24
EP2739153A1 (en) 2014-06-11
EP2739153B1 (en) 2018-08-22
MX359664B (es) 2018-10-05
US20170087132A1 (en) 2017-03-30
WO2013066440A1 (en) 2013-05-10
CA2843417A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
ES2808056T3 (es) Sincronización entre secuencias de imágenes del corazón adquiridas a diferentes frecuencias cardiacas
Saif Advancements in the management of pancreatic cancer: 2013
JP2019536805A5 (enExample)
Beaumont et al. Isotope analysis of incremental human dentine: towards higher temporal resolution
RU2018142394A (ru) Композиции и способы для лечения нейтропении
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
US10720228B2 (en) Method and system for testing of active molecules using molecular simulation of skin membrane
Murray et al. A new species in the Hipposideros bicolor group (Chiroptera: Hipposideridae) from Peninsular Malaysia
Nave et al. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar.
Rasheed Effect of bonding amalgam on the reinforcement of teeth
Costa et al. Characterization of aqueous silver nitrate solutions for leakage tests
Yusoff et al. Pentadbiran Undang-Undang Harta Pusaka Mualaf Di Malaysia: Satu Sorotan Literatur: Administration of Mualaf Inheritance at Wilayah Persekutuan: A Literature Highlights
Machida et al. Aldosterone-, corticosterone-and cortisol-secreting adrenocortical carcinoma in a dog: case report
Sari Efek Paparan Radiasi Gamma dan Pemberian Ekstrak Temulawak (Curcuma xanthorrhiza) terhadap Pelebaran Vena Centralis Hepar Mencit (Mus musculus)
Jeremić et al. Comparison of three methods used for measurement of radioiodine fixation in thyroid gland of mice
Welling The Drug Development Process: Increasing Efficiency and Cost-Effectiveness
Mhingo Australian vaccine could put stop to malaria
Jiménez et al. Hiperparatiroidismo primario e hipoparatiroidismos
Barua et al. Federal Delays in Approving New Medicines 2013
Dumontet et al. P-479 Expression of class III beta tubulin is predictive of patientoutcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
Woloshun Select Amino Acids Enhance or Reduce Iron Absorption Via DMT1 Trafficking for Treatment of Iron-Deficiency Anemia and Iron-Overload Disorders
Iwanaga et al. A novel method for visualization of the inferior alveolar nerve for clinical and educational purposes
Elmekaty et al. 38 Excellence in medication reconciliation during COVID-19 pandemic
Domine et al. P-477 Biweekly carboplatin and gemcitabine for untreated advancednon-small cell lung cancer (NSCLC). A multicenter phase II trial
Lowitz et al. Principles of medical oncology and cancer biology